A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension

Hypertension

Volumn 56, Issue 6, 2010, Pages 1152-1159

  McKie, Paul M ^a   Cataliotti, Alessandro ^a   Boerrigter, Guido ^a   Chen, Horng H ^a   Sangaralingham, S Jeson ^a   Martin, Fernando L ^a   Ichiki, Tomoko ^a   Burnett Jr , John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

aldosterone; angiotensin; atrial natriuretic factor; hypertension; kidney; natriuretic peptides

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; M ATRIAL NATRIURETIC PEPTIDE; NESIRITIDE; UNCLASSIFIED DRUG;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DIURESIS; DOG; GLOMERULUS FILTRATION RATE; HEART RIGHT ATRIUM PRESSURE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; LUNG ARTERY PRESSURE; MALE; MEAN ARTERIAL PRESSURE; NATRIURESIS; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; SYSTEMIC VASCULAR RESISTANCE;

ACUTE DISEASE; ALDOSTERONE; ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; CYCLIC GMP; DIURESIS; DOGS; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; MALE; NATRIURESIS; PULMONARY WEDGE PRESSURE; RENAL CIRCULATION; VASCULAR RESISTANCE;

EID: 78650415786     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.159210     Document Type: Article

References (44)

1. Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol. 2009:341-366.
2. Cody RJ, Atlas SA, Laragh JH, Kubo SH, Covit AB, Ryman KS, Sha-knovich A, Pondolfino K, Clark M, Camargo MJ. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest. 1986;78:1362-1374.
3. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, Najjar SS, Zhao JH, Heath SC, Altshuler D, Strachan DP, Laan M, Meneton P, Wareham NJ, Uda M, Jarvelin MR, Mooser V, Melander O, Loos RJ, Elliott P, Abecasis GR, Caulfield M, Munroe PB. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet. 2009;41:666-676.
4. Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, Guiducci C, Kathiresan S, Benjamin EJ, Struck J, Morgenthaler NG, Bergmann A, Blankenberg S, Kee F, Nilsson P, Yin X, Peltonen L, Vartiainen E, Salomaa V, Hirschhorn JN, Melander O, Wang TJ. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet. 2009;41:348-353.
5. John SW, Krege JH, Oliver PM, Hagaman JR, Hodgin JB, Pang SC, Flynn TG, Smithies O. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science. 1995;267:679-681.
6. Field LJ, Veress AT, Steinhelper ME, Cochrane K, Sonnenberg H. Kidney function in ANF-transgenic mice: effect of blood volume expansion. Am J Physiol. 1991;260:R1-R5.
7. McKie PM, Cataliotti A, Huntley BK, Martin FL, Olson TM, Burnett JC Jr. A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions. J Am Coll Cardiol. 2009;54:1024-1032.
8. Dickey DM, Yoder AR, Potter LR. A familial mutation renders atrial natriuretic Peptide resistant to proteolytic degradation. J Biol Chem. 2009;284:19196-19202.
9. Chen HH, Lainchbury JG, Matsuda Y, Harty GJ, Burnett JC Jr. Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopep-tidase inhibition in experimental mild heart failure. Hypertension. 2001;38: 187-191.
10. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J. 1993;291: 83-88.
11. Lafferty HM, Gunning M, Silva P, Zimmerman MB, Brenner BM, Anderson S. Enkephalinase inhibition increases plasma atrial natriuretic peptide levels, glomerular filtration rate, and urinary sodium excretion in rats with reduced renal mass. Circ Res. 1989;65:640-646.
12. Szczech LA, Granger CB, Dasta JF, Amin A, Peacock WF, McCullough PA, Devlin JW, Weir MR, Katz JN, Anderson FA Jr, Wyman A, Varon J. Acute kidney injury and cardiovascular outcomes in acute severe hypertension. Circulation. 2010;121:2183-2191.
13. Chen HH, Cataliotti A, Schirger JA, Martin FL, Burnett JC Jr. Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure. Am J Physiol Regul Integr Comp Physiol. 2005;288:R1093-R1097.
14. Burnett JC Jr, Kao PC, Hu DC, Heser DW, Heublein D, Granger JP, Opgenorth TJ, Reeder GS. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science. 1986;231:1145-1147.
15. Steiner AL, Parker CW, Kipnis DM. The measurement of cyclic nucle-otides by radioimmunoassay. Adv Biochem Psychopharmacol. 1970;3: 89-111.
16. Haber E, Koerner T, Page LB, Kliman B, Purnode A. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab. 1969;29:1349-1355.
17. Lisy O, Redfield MM, Jovanovic S, Jougasaki M, Jovanovic A, Leskinen H, Terzic A, Burnett JC Jr. Mechanical unloading versus neurohumoral stimulation on myocardial structure and endocrine function In vivo. Circulation. 2000;102:338-343.
18. Sancho J, Haber E. A direct microassay for aldosterone in plasma extracts. J Clin Endocrinol Metab. 1978;47:391-396.
19. Davidson WD, Sackner MA. Simplification of the anthrone method for the determination of inulin in clearance studies. J Lab Clin Med. 1963; 62:351-356.
20. Thomsen K. Lithium clearance as a measure of sodium and water delivery from the proximal tubules. Kidney Int. 1990;28(suppl):S10-S16.
21. Thomsen K, Holstein-Rathlou NH, Leyssac PP. Comparison of three measures of proximal tubular reabsorption: lithium clearance, occlusion time, and micropuncture. Am J Physiol. 1981;241:F348-F355.
22. Margulies KB, Heublein DM, Perrella MA, Burnett JC Jr. ANF-mediated renal cGMP generation in congestive heart failure. Am J Physiol. 1991; 260:F562-F568.
23. Lopez MJ, Wong SK, Kishimoto I, Dubois S, Mach V, Friesen J, Garbers DL, Beuve A. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature. 1995;378:65-68.
24. Hata N, Seino Y, Tsutamoto T, Hiramitsu S, Kaneko N, Yoshikawa T, Yokoyama H, Tanaka K, Mizuno K, Nejima J, Kinoshita M. Effects of carperitide on the long-term prognosis of patients with acute decom-pensated chronic heart failure: the PROTECT multicenter randomized controlled study. Circ J. 2008;72:1787-1793.
25. Morikawa S, Sone T, Tsuboi H, Mukawa H, Morishima I, Uesugi M, Morita Y, Numaguchi Y, Okumura K, Murohara T. Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide. J Am Coll Cardiol. 2009;53:1040-1046.
26. Hayashi M, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Tsutsui T, Horie H, Ohnishi M, Kinoshita M. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol. 2001;37:1820-1826.
27. Edwards BS, Schwab TR, Zimmerman RS, Heublein DM, Jiang NS, Burnett JC Jr. Cardiovascular, renal, and endocrine response to atrial natriuretic peptide in angiotensin II mediated hypertension. Circ Res. 1986;59:663-667.
28. Atarashi K, Mulrow PJ, Franco-Saenz R. Effect of atrial peptides on aldosterone production. J Clin Invest. 1985;76:1807-1811.
29. Kurtz A, Della Bruna R, Pfeilschifter J, Taugner R, Bauer C. Atrial natriuretic peptide inhibits renin release from juxtaglomerular cells by a cGMP-mediated process. Proc Natl Acad Sci USA. 1986;83: 4769-4773.
30. Garcia R, Thibault G, Cantin M, Genest J. Effect of a purified atrial natriuretic factor on rat and rabbit vascular strips and vascular beds. Am J Physiol. 1984;247:R34-R39. (Pubitemid 14090878)
31. Harris PJ, Thomas D, Morgan TO. Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption. Nature. 1987;326:697-698.
32. Kitiyakara C, Guzman NJ. Malignant hypertension and hypertensive emergencies. J Am Soc Nephrol. 1998;9:133-142.
33. Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med. 2002;347:1256-1261.
34. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341:577-585.
35. Pidgeon GB, Richards AM, Nicholls MG, Espiner EA, Yandle TG, Frampton C. Differing metabolism and bioactivity of atrial and brain natriuretic peptides in essential hypertension. Hypertension. 1996;27: 906-913.
36. Kambayashi Y, Nakao K, Mukoyama M, Saito Y, Ogawa Y, Shiono S, Inouye K, Yoshida N, Imura H. Isolation and sequence determination of human brain natriuretic peptide in human atrium. FEBS Lett. 1990;259: 341-345. (Pubitemid 20025830)
37. Seilhamer JJ, Arfsten A, Miller JA, Lundquist P, Scarborough RM, Lewicki JA, Porter JG. Human and canine gene homologs of porcine brain natriuretic peptide. Biochem Biophys Res Commun. 1989;165: 650-658. (Pubitemid 20025571)
38. Clavell AL, Stingo AJ, Aarhus LL, Burnett JC Jr. Biological actions of brain natriuretic peptide in thoracic inferior vena caval constriction. Am J Physiol. 1993;265:R1416-R1422.
39. Pan S, Chen HH, Dickey DM, Boerrigter G, Lee C, Kleppe LS, Hall JL, Lerman A, Redfield MM, Potter LR, Burnett JC Jr, Simari RD. Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide. Proc Natl Acad Sci USA. 2009;106:11282-11287.
40. Cataliotti A, Chen HH, Schirger JA, Martin FL, Boerrigter G, Costello-Boerrigter LC, James KD, Polowy K, Miller MA, Malkar NB, Bailey KR, Burnett JC Jr. Chronic actions of a novel oral B-type natriuretic peptide conjugate in normal dogs and acute actions in angiotensin II-mediated hypertension. Circulation. 2008;118:1729-1736.
41. Huelsemann JL, Sterzel RB, McKenzie DE, Wilcox CS. Effects of a calcium entry blocker on blood pressure and renal function during an-giotensin-induced hypertension. Hypertension. 1985;7:374-379.
42. Imagawa J, Kusaba-Suzuki M, Satoh S. Preferential inhibitory effect of nifedipine on angiotensin II-induced renal vasoconstriction. Hypertension. 1986;8:897-903.
43. Wang CT, Zou LX, Navar LG. Renal responses to AT1 blockade in angiotensin II-induced hypertensive rats. J Am Soc Nephrol. 1997;8: 535-542.
44. De Bold AJ. Cardiac natriuretic peptides: gaining further insights into structure-function relationships. J Am Coll Cardiol. 2009;54:1033-1034.